TABLE 1.
Blood plasma levels of amphotericin B delivered by cochleate p.o. or deoxycholate i.p.a
| Formulation and time posttreatment (h) |
Mean level (ng/ml) ± SD (n) at treatment day(s): |
|||
|---|---|---|---|---|
| Day 15 | Day 17 | Day 19 | Days 15–19 | |
| CAmB, p.o., 25 mg/kg/day |
||||
| 1 | 461 ± 47 | 1,520 ± 395 | 515 ± 181 | 795 ± 542 |
| 6 | 770 ± 197 (4) | 875 ± 251 (3) | 733 ± 123 (3) | 790 ± 184 (10) |
| AmB, i.p., 5 mg/kg/day |
||||
| 1 | 846 ± 310 | 494 ± 99 | 702 ± 457 | 697 ± 323 |
| 6 | 1,308 ± 180 (4) | 1,343 ± 359 (3) | 902 ± 494 (3) | 1,197 ± 368 (10) |
a
A 3-week steady-state experiment was performed to observe the accumulation of amphotericin B in the plasma of mice associated with either CAmB p.o. or AmB i.p. administration. Mice were dosed according to weight for a period of 3 weeks, and blood samples were taken at days 15, 17, and 19 at 1 h posttreatment and 6 h posttreatment.